# Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma

> **NCT00562068** · PHASE1 · UNKNOWN · sponsor: **Cancer Research UK** · enrollment: 30 (estimated)

## Conditions studied

- Lymphoma
- Small Intestine Cancer

## Interventions

- **BIOLOGICAL:** alemtuzumab
- **DRUG:** cyclophosphamide
- **DRUG:** doxorubicin hydrochloride
- **DRUG:** prednisolone
- **DRUG:** vincristine sulfate
- **GENETIC:** polymerase chain reaction
- **OTHER:** flow cytometry
- **OTHER:** laboratory biomarker analysis
- **OTHER:** pharmacological study

## Key facts

- **NCT ID:** NCT00562068
- **Lead sponsor:** Cancer Research UK
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2007-05
- **Primary completion:** 2009-05
- **Final completion:** —
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2013-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00562068

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00562068, "Alemtuzumab and Combination Chemotherapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IV Peripheral T-Cell Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00562068. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*